Ce forum est un lieu d'échanges pour les malades et leur entourage, animé par les bénévoles de l'association albi. Il est gratuit et ouvert à tous, adhérents ou non. Notre mission est de faire connaître nos maladies rares et d'apporter aux malades tout le soutien possible, aussi nous ne faisons pas payer nos services. Mais l'association a besoin de financer son fonctionnement et sa participation à la recherche. Nous avons donc besoin de vous, comme vous avez besoin de la collectivité de malades qu'albi représente: aidez-vous et aidez-nous en devenant adhérent (20 € ou plus) ou faites un don. Cliquez ici, c'est simple et rapide ! albi est une association agréée par le Ministère des Solidarités et de la Santé

action de l'ursolvan

Sites, articles, recherche, congrès et manifestations

Modérateurs : Primerose, daniel

Avatar de l’utilisateur
pstriolo
Messages : 58
Inscription : mar. 18 janv. 2005, 6:52 am
Localisation : blagnac (31)

action de l'ursolvan

Message non lu par pstriolo » ven. 04 févr. 2005, 6:22 pm

Ci jont le résumé (en anglais hélas) d'un nouvel article sur l'efficacité de l'ursolvan.

Gastroenterology. 2005 Feb;128(2):297-303. Related Articles, Links

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.

Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R.

Background & Aims: We used a multistate modeling approach to assess the effect of ursodeoxycholic acid (UDCA) therapy on the natural course of primary biliary cirrhosis (PBC), which remains controversial. Methods: Our population included 262 patients with PBC who had received 13-15 mg/kg UDCA daily for a mean of 8 years (range, 1-22 years). Data were analyzed using a multistate Markov model, with histologic stage progression, death, and orthotopic liver transplantation (OLT) as main end points. Survival without OLT was compared with that predicted by the updated Mayo model and with the expected survival in the control population. Results: Forty-five patients developed cirrhosis, 20 underwent OLT, and 16 died by the censor date. Ten deaths were due to liver disease. The overall survival rates were 92% at 10 years and 82% at 20 years. Survival rates without OLT were 84% and 66% at 10 and 20 years, respectively, which were slightly lower than the survival rate of an age- and sex-matched control population (relative risk [RR], 1.4; P = .1) but better than the spontaneous survival rate as predicted by the updated Mayo model (RR, .5; P < .01). The survival rate of patients in stage 1 and 2 was similar to that in the control population (RR, .8; P = .5), whereas the probability of death or OLT remained significantly increased in treated patients in late histologic stages (RR, 2.2; P < .05). Conclusions: Treatment with UDCA alone normalizes the survival rate of patients with PBC when given at early stages. However, there is a continued need for new therapeutic options in patients with advanced disease.

PMID: 15685541 [PubMed - in process]

les conclusions sont favorables à l'utilisation de l'ursolvan surtout lors des premiers stages de la maladie. Pris dès le début de la maladie, il normalise le taux de survie du patient.

Bises à tous.

Philippe

Répondre